Recently, the 2024 Entrepreneur Magazine 100 Future Unicorns Conference and Entrepreneur Magazine Annual Meeting, themed "Crossing the Alps——Boundless Travelers," grandly opened in Chengdu, and the 2024 Entrepreneur Magazine 100 Future Unicorns list was officially announced.Gravel BiotechRanked on the list due to its outstanding performance and high growth in the biopharmaceutical field.
"Entrepreneur Magazine's Top 100 Future Unicorns" focuses on high-growth companies established within the last 10 years, with valuations ranging from $100 million to $1 billion, that have yet to go public. With a professional perspective, it aims to uncover the emerging commercial forces represented by potential unicorns and discover the driving forces behind the continuous incubation, cultivation, and rapid growth of China's unicorns and potential unicorns.
Grit Biotech's successful ranking is not only a full demonstration of the company's comprehensive strength but also a high recognition by the capital market of Grit Biotech's future high growth.
Grit Bio was founded in 2019 as an innovative pharmaceutical company focused on tumor immunotherapy and cell therapy, with a research pipeline represented by TIL drugs. Grit Bio has completed multiple rounds of equity financing and received support from several well-known venture capital funds both in China and internationally.GT101 Injection, independently developed by Grail Bio, is the first TIL drug in China to be approved for registrational clinical trials and has now entered the pivotal Phase II clinical trial. GT201 Injection, the world's first membrane-bound IL-15 complex-engineered TIL product developed by Grail Bio, has completed dual IND submissions in both China and the United States. The company’s core R&D platforms include the StemTexp® TIL expansion technology platform, StaViral® stable viral production system, ImmuT Finder® immunomodulatory target discovery platform, and KOReTIL® high-efficiency gene knockout system. Based on these platforms, Grail Bio has developed a series of next-generation gene-edited TIL therapeutics. Grail Bio possesses internationally leading technical expertise and industry resources, aiming to create groundbreaking cell therapies for solid tumors and bring new hope to cancer patients worldwide.
